Objective: Early detection of psoriatic arthritis (PsA) can prevent destruction and functional disabilities. Dermatologists play an important role in the early diagnosis and treatment of PsA. The aim of the study was to develop a practical questionnaire that does not take long time for early diagnosis of PsA and for not to overlook axial involvement. Material and Methods: This was a prospective study including 200 psoriasis patients. Turkish Psoriatic Arthritis Screening Tool (TUPAST) questions were designed in a simple and plain language that the patients could easily understand. Patients were asked to answer these 6 questions and the well-known questionnaire Toronto Psoriatic Arthritis Screening 2 (ToPAS 2) synchronously. Results: ROC analysis was performed to determine the cut-off value of TUPAST, and the cut-off value was determined as 3. The sensitivity of the cut-off value was calculated as 54.32% and the specificity as 90.68%. The cut-off value obtained for ToPAS 2 was 8 and its sensitivity was 79%, and specificity was 55% in our patient population. There was a significant difference between two tests in terms of time spent for answering questions (TUPAST-0.5 minute, ToPAS 2-3.6 minute) (p<0.05). Conclusion: PsA screening by dermatologist can be the first step in diagnosis of joint involvement in psoriasis. Due to the heavy patient traffic of dermatology outpatient clinics, we need tests that do not take much time. TUPAST is a simple and time saving screening test that takes only 30 seconds to answer and can be used in prediagnosis of PsA.
Keywords: Psoriasis; psoriatic arthritis; screening test; Toronto Psoriatic Arthritis Screening 2; Turkish Psoriatic Arthritis Screening Tool
Amaç: Psöriyatik artritin (PsA) erken tespiti, eklem destrüksiyonu ve işlev kaybını önleyebilir. Dermatologlar, PsA'nın erken tanı ve tedavisinde önemli bir rol oynamaktadır. Çalışmamızın amacı, PsA'nın erken tanısı için uzun zaman almayan ve aksiyel tutulumu gözden kaçırmayan pratik bir anket geliştirmektir. Gereç ve Yöntemler: Çalışmamız, 200 psöriyazis hastasını kapsayan prospektif bir çalışmaydı. Türk Psoriatik Artrit Tarama Anketi [Turkish Psoriatic Arthritis Screening Tool (TUPAST)] soruları hastaların anlayabileceği sade bir dilde hazırlandı. Hastalardan bu 6 soru ve Toronto Psoriatik Artrit Tarama 2 [Toronto Psoriatic Arthritis Screening 2 (ToPAS 2)] anketini eş zamanlı olarak cevaplamaları istendi. Bulgular: TUPAST'ın eşik değerini belirlemek için ROC analizi yapıldı ve eşik değeri 3 olarak belirlendi. Eşik değerin duyarlılığı %54,32, özgüllüğü %90,68 olarak hesaplandı. ToPAS 2 için elde edilen eşik değer 8 olup duyarlılığı %79, özgüllüğü ise hasta popülasyonumuzda %55 olarak bulundu. Soruları cevaplamak için harcanan süre açısından iki test arasında anlamlı fark vardı (TUPAST-0,5 dk, ToPAS 2-3,6 dk) (p<0,05). Sonuç: Dermatolog tarafından yapılan PsA taraması, sedef hastalığının eklem tutulumunun tanısında ilk adım olabilir. Dermatoloji polikliniklerinin yoğun hasta trafiğinden dolayı fazla zaman almayan testlere ihtiyaç duyulmaktadır. TUPAST, PsA ön tanısında kullanılabilen, cevaplanması sadece 30 sn süren, basit ve zaman kazandıran bir tarama testidir.
Anahtar Kelimeler: Psöriyazis; psöriyatik artrit; tarama testi; Toronto Psoriatik Artrit Tarama 2; Türk Psoriatik Artrit Tarama Anketi
- Lindqvist UR, Alenius GM, Husmark T, Theander E, Holmström G, Larsson PT; Psoriatic Arthritis Group of the Society for Rheumatology. The Swedish early psoriatic arthritis register-- 2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol. 2008;35(4):668-73. [PubMed]
- Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii14-7. [Crossref] [PubMed] [PMC]
- Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242-8. [Crossref] [PubMed]
- Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851-64. [Crossref] [PubMed]
- Gladman DD. Axial disease in psoriatic arthritis. Curr Rheumatol Rep. 2007;9(6):455-60. [Crossref] [PubMed]
- Tom BD, Chandran V, Farewell VT, Rosen CF, Gladman DD. Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2). J Rheumatol. 2015;42(5):841-6. [Crossref] [PubMed]
- Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57(4):581-7. [Crossref] [PubMed]
- Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27(3):469-74. [PubMed]
- Tinazzi I, Adami S, Zanolin EM, Caimmi C, Confente S, Girolomoni G, et al. The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. Rheumatology (Oxford). 2012;51(11):2058-63. [Crossref] [PubMed]
- Duruöz MT, Şanal Toprak C, Ulutatar F. Validation of the Toronto Psoriatic Arthritis Screen II (TOPAS II) questionnaire in a Turkish population. Rheumatol Int. 2018;38(2):255-9. [Crossref] [PubMed]
- Belinchón I, Salgado-Boquete L, López-Ferrer A, Ferran M, Coto-Segura P, Rivera R, et al. Dermatologists' role in the early diagnosis of psoriatic arthritis: expert recommendations. Actas Dermosifiliogr (Engl Ed). 2020;111(10):835-46. English, Spanish. [Crossref] [PubMed] [PMC]
- Bagel J, Schwartzman S. Enthesitis and dactylitis in psoriatic disease: a guide for dermatologists. Am J Clin Dermatol. 2018;19(6):839-52. [Crossref] [PubMed] [PMC]
- Gladman DD, Schentag CT, Tom BD, Chandran V, Brockbank J, Rosen C, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis. 2009;68(4):497-501. [Crossref] [PubMed]
- Iragorri N, Hazlewood G, Manns B, Danthurebandara V, Spackman E. Psoriatic arthritis screening: a systematic review and meta-analysis. Rheumatology (Oxford). 2019;58(4):692-707. [Crossref] [PubMed] [PMC]
- Oyur KB, Engin B, Hatemi G, Asma A, Kutlubay Z, Bulut N, et al. Turkish PASE: Turkish version of the psoriatic arthritis screening and evaluation questionnaire. Ann Dermatol. 2014;26(4):457-61. [Crossref] [PubMed] [PMC]
- Audureau E, Roux F, Lons Danic D, Bagot M, Cantagrel A, Dernis E, et al. Psoriatic arthritis screening by the dermatologist: development and first validation of the 'PURE-4 scale'. J Eur Acad Dermatol Venereol. 2018;32(11):1950-3. [Crossref] [PubMed]
.: Process List